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Abstract
Background: The antibody-based targeted delivery of bioactive molecules to tumour vasculature is an attractive
avenue to concentrate therapeutic agents at cancer sites, while sparing normal organs. L19, F8 and F16 are three
fully human monoclonal antibodies, specific to splice isoforms of fibronectin and tenascin-C, which bind to sites of
active tissue remodeling and which are currently in Phase I and II clinical trials as radio-immunoconjugates and
immunocytokines in patients with cancer and arthritis.
In this article, we report the first comparative analysis of expression patterns for the extra domains EDB and EDA of
fibronectin and A1 of tenascin-C in both primary and metastatic head and neck cancer lesions.
Methods: We performed a comparative immunofluorescence analysis with the L19, F8 and F16 antibodies in 40
freshly frozen human head and neck cancer specimens.
Results: On average, F8 and F16 exhibited similar staining intensities, which were typically stronger than L19.
Interestingly, some specimens exhibited striking differences in staining by the three antibodies.
Conclusions: These results suggests that an individualized treatment procedure (e.g., choice of L19, F8 or F16
based on immuno-PET or immunofluorescence procedure) may represent the most logical avenue for offering the
best possible antibody to any given patient.
Background
Antibody-based anti-cancer pharmacodelivery strategies
critically rely on the availability of good-quality tumour
markers, allowing a clear differentiation between dis-
eased tissue and healthy organs. Markers of the tumour
neovasculature are particularly attractive, because of the
dependence of tumours on new blood vessels to sustain
growth and invasion, and because of the accessibility of
these structures from the bloodstream. Furthermore,
angiogenesis is a common feature of virtually all malig-
nancies [1,2].
The alternatively spliced extra domain A (EDA) and B
(EDB) of fibronectin and A1 domain of tenascin-C
represent three of the best-characterized markers of
angiogenesis and have been reported to be expressed
around the neo-vasculature and in the stroma of
virtually all types of aggressive solid tumours. Three
human monoclonal antibodies specific to these targets
have been developed by our groups and moved to clini-
cal trials: L19 (specific to EDB) [3], F8 (specific to EDA)
[4] and F16 (specific to the A1 domain of tenascin-C)
[5]. Several antibody derivatives, based on the modifica-
tion of L19, F8 or F16 with cytokines or iodine radionu-
clides, are currently investigated in Phase I and Phase II
clinical trials in patients with cancer and with rheuma-
toid arthritis [6,7]. These biopharmaceuticals are called
L19-124I, L19-131I, L19-IL2, L19-TNF, F8-IL10, F16-124I,
F16-131I, F16-IL2, indicating the modular nature of
these derivatives, in which the antibody moiety is used
to deliver a payload at the site of disease.
The staining patterns of the L19 and F16 antibody in
head and neck tumours [5,8] have previously been pub-
lished by our group in separate articles, but the relative
staining intensities of the two antibodies have so far not
been compared. Furthermore, a radioiodinated version
of the L19 antibody has been tested in scFv format in a
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small immunoscintigraphic clinical study in patients
with head and neck squamous cell carcinomas (SCC),
observing tumour localization in 4 of 5 patients [9].
More recently, radioiodinated derivatives of both L19
and F16 antibodies in SIP format [5,10] have been stu-
died in Phase II clinical trials in over 100 patients with
cancer, including head and neck cancer patients [6]
[unpublished results].
In this article, we report the first comparative analysis
of expression patterns for the extra domains EDB and
EDA of fibronectin and A1 of tenascin-C in both pri-
mary and metastatic head and neck cancer lesions.
Methods
Specimens
A total of 40 freshly frozen OCT embedded tissue sam-
ples were obtained from the University Hospital of Salz-
burg (Austria), Department of ear-nose-throat diseases.
This study was examined by the ethical committee of
the province Salzburg and patient consents for the tissue
collection were obtained prior to surgery. The speci-
mens were collected during major head and neck
tumour operations (table 1). The tissues were stored at
-80°C. Sections of 10 μm were cut.
Immunofluorescence staining
The L19 antibody, specific to the extra domain B (EDB)
of fibronectin, the F8 antibody, specific to the extra
domain A (EDA) of fibronectin, and the F16 antibody,
specific to the extra domain A1 of tenascin-C, have
been described before [3-5]. All antibodies were isolated
from ETH2 antibody libraries, affinity matured, had dis-
sociation constants in the low nanomolar range and
exhibited kinetic dissociation constants koff towards the
respective antigens <10-2s-1 in real-time interaction ana-
lysis experiments on a BIAcore 3000 instrument (GE
Healthcare, Zurich, Switzerland). As a negative control
the antibody KSF was used. KSF is specific to hen egg
lysozyme and does not show any specificity towards
human antigens. All antibodies were biotinylated and
carried a comparable number of biotin molecules.
For immunofluorescence, a double staining for EDA,
EDB resp. TnC-A1 and von Willebrand factor was per-
formed. The following primary antibodies were used:
biotinylated F8, L19, F16 and KSF (negative control anti-
body) in small immunoprotein format (SIP) (2 μg/ml for
all four antibodies) and polyclonal rabbit anti-human
von Willebrand factor (Dako, Glostrup, Denmark). For
detection of the biotinylated SIPs Streptavidin Alexa
Fluor 488 (Invitrogen, Basel, Switzerland) was used. As
secondary detection antibody for the anti-von Willeb-
rand factor antibody Alexa Fluor 488 goat anti-rabbit
(Invitrogen, Basel, Switzerland) antibody was used.
Cryosections were fixed in chilled aceton, rehydrated
in PBS (100 mM NaCl, 30 mM Na2HPO4, 20 mM
NaH2PO4, pH 7.4) and blocked with 20% goat serum in
PBS. Primary antibodies were added in a final concen-
tration of 2 μg/ml in 3% bovine serum albumin (BSA)/
PBS solution and incubated for 1 h. After washing in
PBS secondary antibodies were added in 3% bovine
serum albumin (BSA)/PBS solution and incubated for 1
h. Sections were washed in PBS and mounted with
fluorescent mounting medium (Dako, Glostrup, Den-
mark) and analyzed with a confocal laser scanning
microscope (LSM 510 META, Zeiss, Oberkochen, Ger-
many). Microscopic exposure times were identical for all
antibodies. Images were further processed using the
ImageJ software http://rsb.info.nih.gov/ij.
Semi-quantitative evaluation of results
Staining intensities of the extra domains A and B of
fibronectin and the A1 domain of tenascin C were inde-
pendently assessed by experienced investigators. Staining
was scored using 7 scores: 0, 0.5, 1, 1.5, 2, 2.5 and 3,
according to a training table, representing a selection of
the corresponding staining intensities as reference. Data
are expressed as the mean ± standard error of the mean.
Results and Discussion
The staining intensities of biotinylated derivatives of the
L19, F8 and F16 antibodies in 40 frozen specimens of
head and neck cancer were studied by three-colour
immunofluorescence microscopy. The tissue series
included tumours of the oral cavity, the pharynx and
the larynx [table 1]. Primary benign lesions, malignant
tumours as well as metastatic cancer specimens were
analyzed. The three antibodies L19, F8 and F16 had
comparable high affinities towards their cognate antigen
and were used in identical concentrations. The KSF
antibody, specific to hen egg lysozyme and with no
known reactivity towards human antigens [11], was used
as negative control (data not shown). Figure 1 shows
representative immunofluorescence findings with the
three antibodies (green) in different tumour sections.
Cell nuclei were stained with DAPI (blue), while blood
vessels were coloured in red using an anti-von Willeb-
rand antibody. In most specimens, all three antibodies
exhibited a diffuse stromal staining, similar to previously
described patterns of fibronectin and tenascin-C expres-
sion [12,13]. Interestingly, some specimens exhibited
striking differences in staining by the three antibodies
[Figure 1]. This observation suggests that, while at least
one of the three antibodies is generally capable of inten-
sely staining a given tumour, an individualized treatment
procedure (e.g., choice of L19, F8 or F16 based on
immuno-PET or immunofluorescence procedure) may
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represent the most logical avenue for offering the best
possible antibody to any given patient.
Figure 2 presents a semi-quantitative analysis of stain-
ing intensities of L19, F8 and F16, ranging from 0
(absent), to 3 (+++). Independent investigators assessed
all pictures, assigning a scoring intensity to each speci-
men. The average of these values and the corresponding
standard error were displayed in the figure. Primary
tumours and metastatic tumour lesions as well as pri-
mary benign and malign tumours were analyzed, as well
as tumour samples from different anatomical locations
(oral cavity, larynx and pharynx). On average, F8 and
F16 exhibited similar staining intensities, which were
typically stronger than L19. As a consequence, armed
antibodies based on F8 or F16 may represent the best
choice for the treatment of head and neck cancer,
Table 1 Description of samples used for the immunofluorescence analysis
Sample No. Primary tumor/
LN metastasis1
Tissue origin Histological result2
1 tumour parotid gland PA
2 metastasis lymph node SCC
3 tumour hypopharynx SCC
4 tumour hypopharynx SCC
5 tumour uvula SCC
6 tumour skin (left auricle) BCC
7 metastasis lymph node SCC
8 tumour hypopharynx SCC
9 metastasis (from 8) lymph node SCC
10 metastasis lymph node SCC
11 tumour skin (nose) SCC
12 tumour hypopharynx SCC
13 tumour oral cavity (tongue) SCC
14 metastasis (from 13) lymph node SCC
15 metastasis (from 8) lymph node SCC
16 tumour parotid gland PA
17 tumour oropharynx SCC
18 tumour oropharynx SCC
19 tumour parotid gland PA
20 tumour parotid gland PA
21 tumour hypopharynx SCC
22 tumour larynx (vocal cord) SCC
23 tumour larynx SCC
24 tumour larynx SCC
25 metastasis lymph node CS
26 tumour oropharynx (tonsil) SCC
27 tumour larynx SCC
28 tumour oropharynx SCC
29 tumour supraglottis SCC
30 tumour supraglottis SCC
31 tumour supraglottis SCC3
32 tumour oral cavity (lower jaw - alveolar crest) SCC
33 tumour larynx (glottis - posterior commissure) SCC
34 tumour oral cavity (palatal arch) SCC
35 tumour nasopharynx SCC
36 metastasis lymph node PDTC
37 metastasis lymph node SCC
38 tumour oropharynx (vallecula epiglottica) SCC
39 tumour larynx (epiglottis) SCC
40 tumour larynx (epiglottis) SCC
1 Indication of primary tumour sample (LN: cervical lymph node). 2 Abbreviations: SCC: squamous cell carcinoma; PA: pleomorphic adenoma (benign); CS:
carcinosarcoma; PDTC: poorly differentiated thyroid carcinoma; BCC: basal cell carcinoma. 3 Status post radiotherapy.
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Figure 1 Immunofluorescence staining of head and neck cancer samples. The expression patterns and intensities of the splice isoforms
extra domain A (EDA) and extradomain B (EDB) of fibronectin and the A1 domain of tenascin C were detected with the antibodies F8, L19 and
F16, respectively (shown in green). A co-staining with an anti-von Willebrand factor antibody that stains blood vessels (red) and Dapi (blue) was
performed. Abbreviations: SCC: squamous cell carcinoma; PA: pleomorphic adenoma.
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whereas L19 may be more appropriate for other cancer
types which strongly express the EDB domain of fibro-
nectin (e.g., kidney cancer; [7]). However, it cannot be
excluded that the weaker staining observed for EDB
may be a consequence of lower stability of this antigen,
which has been reported in case of tissue section storage
at -80°C for longer than 20 days [14]. In a previous
study, a radioiodinated version of the L19 antibody has
been tested in scFv format in a small immunoscinti-
graphic clinical study in patients with head and neck
squamous cell carcinomas. Successful targeting of the
primary tumour could be achieved in 4 out of 5 patients
[9]. Further imaging studies are needed to reveal
whether targeting of F16 and F8 is superior to L19 in
head and neck cancer patients. Indeed, two Phase II
clinical trials with SIP(L19) [6] and SIP(F16) labelled
with 124I [15] are currently being performed.
Conclusions
The majority of head and neck cancer types exhibited a
diffuse pattern of expression for splice isoforms of
fibronectin and of tenascin-C. The clinical stage antibo-
dies F8 and F16 stained tumours more intensely com-
pared to L19 and may thus represent the most suitable
candidates to be used as vehicles for pharmacodelivery
applications.
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